|
Weekly-market: Year 2012 winds up with gains of over 1% for Indian markets
|
Saturday, December 29, 2012 |
| Market Commentary | | Year 2012 winds up with gains of over 1% for Indian markets | The Indian markets wrapped the last week of the year 2012 in the green zone breaking the losing trend of last two-weeks. The Sensex rose 1.05% and the Nifty was up by 1.03% for the week ended Dec 28, 2012. |
Major Headlines for the week: Indian indices Welcome to the 'Weekly Market Wrap' for the week ended December 28, 2012. The Indian markets wrapped up the week ended December 28, 2012 in the green zone. The key indices were in consolidation mode and remained in a tight range throughout the week. After a negative trend for the past two-weeks, the markets witnessed lackluster trade and did not show any major movements. There were no great triggers to lift markets higher, which led the key indices to trade in a narrow range throughout this week. The market sentiments got boosted by data showing that foreign institutional investors (FIIs) remained buyers of Indian stocks during the week. In the week gone three new companies got listed: -
Shares of Credit Analysis & Research (CARE) surged on its listing day on Wednesday, (December 26, 2012). -
Shares of PC Jeweller listed with modest gains on its debut on Thursday, (December 27, 2012). -
Shares of Bharti Infratel plunged on debut on Friday, (December 29, 2012). The markets gained in three out of four trading sessions in the truncated week gone by. The BSE Mid-Cap index advanced 1.36% while the BSE Small-Cap index gained 0.23%. The BSE Sensex rose 202.84 points or 1.05% to 19,444.84 while the NSE Nifty gained 60.65 points or 1.03% to 5,908.35 in the week. Weekly market trend from December 24 - December 28, 2012 -
The key benchmark indices opened the week on a positive note on December 24, 2012. The Indian markets closed trading session on a flat note. The traders booked profits ahead of Christmas holiday and expiry of December derivative contracts. The Sensex shut shop at 19255, up by 13 points while the Nifty rose 8 points to close at 5855. -
On December 25, 2012, the markets remained closed on account of Christmas. -
On December 26, 2012, the domestic markets rose nearly 1%, ahead of F&O expiry. Banking stocks gained on hopes of easing liquidity as the Reserve Bank of India continues with cash injection measures and on expectations of a rate cut in next month. The Sensex closed at 19417.46, up by 162.37 points, while the Nifty rose by 49.85 points to close at 5905.6 -
On December 27, 2012, the key indices ended near day's low on December F&O expiry day as traders rolled over positions to the January series. The Sensex settled at 19323.80, down by 93.66 points, while the Nifty shut shop at 5870.10, down by 35.50 points. -
On December 28, 2012, the rise in the market was led by oil shares on the back of the proposed gradual hike in diesel and kerosene prices. The Sensex shut shop at 19,444.84, up by 121.04 points, while the Nifty rose 38 points to close at 5,908.35. Global indices All the global markets closed mixed this week. Top gainers: Nikkei rose by 4.58% and Shanghai Composite surged by 3.71% and Hang Seng up by 0.71%. On the other side, top losers were Nasdaq, which was down by 2.01%, Dow Jones fell 1.92% and CAC40 slipped 1.12%. Sectoral and stock screening: All the sectors closed the week on a positive note. BSE Oil & Gas rose by 2.05%, followed by Realty which surged by 2.02%, Power up by 1.68% and CG advanced by 1.58%. | Looking at the 'A' group stocks, top three gainers of the week were - Madras Cement up by 9.89%, NHPC rose by 8.25% and Gitanjali Gems up by 7.81%. Top three losers of the week were - TTK Prestige fell by 4.80%, Astrazenca Pharma down by 4.23% and Strides Arcolab fell by 3.35%. FII/MF activity: The foreign institutional investors (FIIs) have been the net buyers Indian stocks to the tune of Rs4829.9 crore till December 27, 2012. The domestic investors sold Indian shares worth a net of Rs110.8 crore on December 24, 2012. | TOP MOVERS (GROUP A) |  | | | | | Madras Cement | 249.40 | 9.89 | | | Gitanjali Gems | 510.90 | 7.81 | | | TTK Prestige | 3,249.60 | -4.80 | | Astrazenca Pharma | 1,340.55 | -4.23 | | Strides Arcolab | 1,074.95 | -3.55 | | | | | | FII/MF ACTIVITIES |  | | | | Gross purchase | 11,038 | 289 | | | Net investment | 4,828 | -110 | | | | | | | | *Data as on December 27, 2012 **Data as on December 24, 2012 | | | Market Outlook The Indian markets will soon enter the crucial period of corporate earnings. Third quarter December 2012 earnings will be a major trigger driving the sentiments next week. Automobile and cement stocks will be in focus as the companies from these two sectors start unveiling their monthly sales volume data for November 2012 from Tuesday, (January 01, 2013). The results of monthly surveys on manufacturing and service sector, automobile and cement sales data for December 2012 will also capture limelight in the coming week. Markit Economics will unveil HSBC India Manufacturing PMI, which gauges the business activity of India's factories for December 2012 on Wednesday, (January 02, 2013) and also HSBC India Services PMI and HSBC India Composite PMI for December 2012 on Friday, (January 04, 2013). | | | | | | | | | To know more about our products and services, click here. | | Sharekhan Ltd., Regd Add: 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai - 400 042, Maharashtra. Tel: 022 - 61150000. BSE Cash-INB011073351; F&O-INF011073351; NSE - INB/INF231073330; CD - INE231073330; MCX Stock Exchange : CD - INE261073330 DP: NSDL-IN-DP-NSDL-233-2003; CDSL-IN-DP-CDSL-271-2004; PMS INP000000662; Mutual Fund: ARN 20669. | | | "This document has been prepared by Sharekhan Ltd. This Document is subject to changes without prior notice and is intended only for the person or entity to which it is addressed to and may contain confidential and/or privileged material and is not for any type of circulation. Any review, retransmission, or any other use is prohibited. Kindly note that this document does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report. The information contained herein is from publicly available data or other sources believed to be reliable. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. We do not represent that information contained herein is accurate or complete and it should not be relied upon as such. This document is prepared for assistance only and is not intended to be and must not alone betaken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. SHAREKHAN & affiliates may have used the information set forth herein before publication and may have positions in, may from time to time purchase or sell or may be materially interested in any of the securities mentioned or related securities. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. Any comments or statements made herein are those of the analyst and do not necessarily reflect those of SHAREKHAN." | To unsubscribe write to myaccount@sharekhan.com
| | | www.sharekhan.com to manage your newsletter subscriptions | |
posted by Anonymous @ 12:24 AM  |
|
|
|
|